雷帕鸣怎么服用效果好

(sirolimus) was officially approved by the US FDA in September 1999. It is mainly used to prevent and treat rejection of kidney, liver and other transplants. It is especially suitable for patients with concurrent renal dysfunction, tremor and hypertension. The drug has low oral bioavailability, large inter-individual pharmacokinetic (PK) differences, and is a substrate of CYP3A and P glycoprotein (PgP), which can cause drug-drug interactions with a variety of drugs.

When patients who take calcineurin inhibitor drugs after kidney transplantation develop chronic allograft nephropathy, using sirolimus (i.e. rapamycin) instead of calcineurin inhibitor drugs can improve renal function to a certain extent.

In a multicenter clinical study, 31 patients with chronic allograft nephropathy diagnosed by kidney transplant biopsy were switched from calcineurin inhibitors to sirolimus, with an average follow-up of 21.6 months. The results showed that 1 year after switching therapy, the patient's renal function was significantly improved [cGFR: (40.8±2.36) mL/min vs. (55.7±3.6) mL/min; P < 0.0001]. No kidney transplant loss or patient death was observed during follow-up. One year after switching therapy, a procedural biopsy found that 8 (30%) patients had improved, 11 (42%) had stable performance, and 7 (28%) had worsened in terms of renal interstitial fibrosis/tubular atrophy, glomerulosclerosis, and chronic vascular disease scores.

During the actual treatment process, if patients want to achieve good therapeutic effects, they need to master the correct medication method: clinical recommendations are to use this drug in combination with cyclosporine and corticosteroids, and it can be taken orally once a day, regularly with or without food. Since the bioavailability of crushed, chewed, or cut tablets has not been established, patients are advised to swallow the tablets whole during administration.

Recommended hot articles: /newsDetail/72969.html